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Department of Respiratory Diseases, University Hospital of Aarhus, DK-8000 Aarhus, Denmark 
It is logical to look upon the nose and the bronchi as integrated parts of one ‘united airway’ and we would like to 
advance the hypothesis that optimal management of airway disease, caused by inhaled allergens, may necessitate 
control of inflammation in all parts of the airways. Nasal inflammation can aggravate asthma symptoms, and there 
is a rationale for giving intranasal anti-inflammatory treatment to patients with asthma. (i) Inhaled allergens are 
predominantly deposited in the nose, whether a patient suffers from rhinitis, asthma or both. (ii) Antigen 
presentation consequently takes place in the nose, and the response of the airway immune system is thus initiated in 
the nasal mucous membrane. (iii) Antigen presentation in the nose may possibly induce cell recruitment and 
activation not only in the nasal mucosa but also in the lower airways. (iv) Suppression of nasal inflammation may 
therefore be necessary for optimal management of asthma. 
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Introduction 
It is common clinical practice to treat rhinitis and asthma as 
two separate diseases, using intranasal corticosteroids (and 
antihistamines) for nasal symptoms, and orally inhaled 
corticosteroids (and bronchodilators) for asthma. It seems 
logical, however, to look upon the airways as a single entity 
from the tip of the nose to the alveoli, and evidence is 
accumulating that nasal inflammation can influence 
the lower airways and that intranasal anti-inflammatory 
treatment may have a beneficial effect on asthma (1). 
Below, we will discuss an issue which, with a popular 
term, can be called the ‘united airways’ concept. It presents 
the rationale for treating the nose in asthma patients. 
We will emphasize that this concept is based largely on 
speculations, and at present there is no strong case for 
changing the therapeutic practice. However, we hope that 
the hypothesis presented may be an inspiration for the 
performance of controlled studies, which may or may not 
confirm the hypothesis. 
Rhinitis and Asthma are Inflammatory 
Diseases 
It is our starting point that both allergic rhinitis and asthma 
are inflammatory consequences of allergic sensitization and 
reaction to inhaled allergens, at least when the diseases 
begin in childhood and adolescense (2). 
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The Nose is a Filter 
It is normal to breathe through the nose, which acts as a 
filter for the inhaled air, thereby protecting the delicate 
structures in the lower airways (3). Due to its specialized 
anatomy, the nose is an efficient filter, retaining the 
majority of particles, larger than lO,~m, and this includes 
pollen grains and mite faeces pellets (4). A part of small 
particles in the inhaled air will also be deposited in the nose 
due to turbulence of the inhaled airstream behind the 
narrow entrance, the internal ostium localized 1.5 cm from 
the nostril (5). At least 50% of the entire resistance to the 
inhalation is localized to the internal ostium (6), which 
indicates that this area plays an important role in normal 
airway physiology. 
Antigen Deposition and Presentation in 
the Nose 
Fokkens and coworkers have shown that the nasal mucosa 
contains potent antigen-presenting cells which have the 
characteristics of dendritic Langerhans cells (7). As a major 
part of inhaled allergens, as mentioned, are deposited in the 
nose, it follows that antigen presentation takes place mainly 
in the nasal mucosa, whether a patient suffers from rhinitis, 
asthma or both. The number of nasal antigen-presenting 
Langerhans cells is increased by experimental allergen 
challenge and in symptomatic allergic rhinitis (7). 
Immunological Homing 
As T lymphocytes cannot directly recognize antigen in 
solution, their stimulation requires antigen processing and 
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presentation by antigen-presenting cells. This probably 
takes place in the nasal mucosa and in the regional lymph 
nodes. 
The activated T cells ‘home’ in the mucous membrane, 
initially stimulated by the antigen. It is known from studies 
of the gastrointestinal tract that homing is not confined 
exclusively to the antigen-stimulated mucous membrane, 
but occurs also in adjacent mucosal areas (8). If the same 
applies to the airways, it means that antigen deposition and 
presentation in the nose may result in T-cell-induced 
inflammation in the bronchi. This issue, significant for our 
hypothesis, needs further investigation in the airways. 
Release of Cytokines and Mediators 
Leads to Cell Recruitment and Activation 
When the allergen reacts with mediator cells in the nasal 
mucosa, they generate and release cytokines, chemokines 
and mediator substances (9). These molecules recruit the 
inflammatory cells by upregulation of adhesion molecules 
in the nasal vasculature (9). However, cytokinesl 
chemokines and mediators are also released to the circula- 
tion, and it is possible that these molecules can recruit and 
activate circulating inflammatory cells, which may reach not 
only the nasal mucosa but also other parts of the airways. 
These speculations on an effect of nasal antigen stimula- 
tion and allergic inflammation on the lower airways have 
gained support from observations that an allergen challenge 
in the nose increased bronchial reactivity in asthma patients 
(10-12). 
Effect of Intranasal Corticosteroid 
Treatment on Lower Airways 
A number of studies have shown that intranasal cortico- 
steroid treatment for allergic rhinitis has a beneficial 
effect on non-specific bronchial responsiveness and on 
asthma symptoms (13-20). There are at least two possible 
explanations of this phenomenon. 
1. Intranasal corticosteroid treatment results in a dramatic 
reduction in the number of nasal antigen-presenting 
Langerhans cells (7). This inhibition of the initial step in 
the allergic sensitization and reaction may have the 
potential of inhibiting not only allergic inflammation in 
the nose but also in the bronchi, as described above. 
2. We have recently shown that intranasal corticosteroid 
therapy not only abolishes the allergen-induced increase 
in the number of eosinophils and of eosinophil markers 
in nasal lavage fluid but also in the circulation (21). It 
seems likely that the treatment inhibits the release of 
cytokineslchemokines and the subsequent upregulation 
of adhesion molecules in the allergen-challenged nose, 
which may be the cause of the reduced eosinophil 
recruitment and activation, locally and systemically. 
Thus, it is possible that intranasal treatment may reduce 
the cytotoxic effect of eosinophil proteins in the entire 
airway mucosa. 
Therapeutic Implications 
The above theoretical speculations and experimental obser- 
vations indicate that treatment of nasal inflammation may 
be required in order to obtain full control of bronchial 
inflammation and asthma symptoms. There is now a series 
of placebo-controlled therapeutic trials which support this 
hypothesis. 
Some rhinosurgeons claim, on the basis of uncontrolled 
observations, that radical surgical removal of the pathologi- 
cally changed mucous membrane in the paranasal sinuses 
can improve the asthma condition in patients with 
nasal polyposis, hyperplastic sinusitis and non-allergic 
asthma (22). 
There is anecdotal evidence, and a few clinical studies, 
which suggest that treatment of upper airway infection and 
inflammation may be necessary for the full control of 
exacerbations of asthma in childhood (23,24). Before these 
observations can result in a changed therapeutic practice, 
they must be confirmed in controlled prospective trials. 
Also, studies of the effect of intranasal corticosteroids on 
recalcitrant asthma in children and in adults are warranted. 
Nasal Inhalation of Corticosteroid for the 
Simultaneous Treatment of Rhinitis and 
Asthma 
Rhinitis and asthma can be treated simultaneously by a 
single nasal inhalation of corticosteroid through a spacer 
device. We have found a pronounced clinical effect of this 
treatment on both rhinitis and asthma symptoms in pollen- 
allergic adults (25) and there is a similar effect in children 
with perennial rhinitis and asthma (26). 
In principle, a nasal inhalation of an anti-inflammatory 
drug is more logical than an oral inhalation in patients with 
allergy to inhalants, because allergens are deposited in the 
nose and not in the mouth. In addition, local adverse effects 
in the mouth can be avoided completely. 
However, there are also arguments against nasal inhala- 
tion. First, more corticosteroid is absorbed from the nasal 
mucosa than from the mouth. Second, a 50% larger dose is 
needed in order to obtain a similar bronchial deposition 
with nasal as compared with oral inhalation (27,28). There- 
fore, it is too early to say whether a nasal inhalation will 
have a better therapeutic index than an oral inhalation. 
However, we find it logical to deposit corticosteroid in a 
way similar to that of the inhaled allergen. If the nose is not 
treated, potentially harmful inflammatory reactions will 
continue in asthmatic patients. 
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